Law firm probes fairness of AtaiBeckley sale to Eli Lilly amid shareholder concerns over low price.

Wohl & Fruchter LLP is investigating whether the proposed sale of AtaiBeckley to Eli Lilly at $6.75 per share plus a contingent value right (CVR) up to $2.50 is fair to shareholders. The deal price is significantly below Wall Street analysts' targets, which ranged from $14 to $25 per share, causing shareholder dissatisfaction. The law firm is examining if AtaiBeckley's board acted in shareholders' best interests and if all material information was disclosed. Shareholders with concerns are encouraged to contact the firm for legal advice at no charge.